Abstract
Background: Malaria is the parasitic disease caused by Plasmodium infection, and is transmitted to humans through the bite of female anopheles. At present, malaria remains the most important cause of disease and death among children and adults. Approximately 214 million people are infected with malaria worldwide. Objectives: This study aimed to analyze the distribution level and compare procalcitonin and C-reactive protein (CRP) in malaria patients before and after treatment, with focus on discussing the prognostic value of procalcitonin recovery level for recrudescence within two weeks of antimalarial treatment. Methods: A retrospective analysis was adopted. We measured the procalcitonin and CRP inflammatory markers of 22 imported malaria patients, who were hospitalized in our hospital from January 2014 to February 2018. The trends of procalcitonin and CRP levels in three malaria patients before and after antimalarial treatment and during recrudescence were applied. Results: The procalcitonin level was significantly elevated before antimalarial treatment in 95% (21/22) of the patients, but sharply declined within two weeks after treatment. The procalcitonin levels of 59% (13/22) and 23% (5/22) of the patients were 1.0 ng/mL and failed to recover to the normal level within two weeks after antimalarial treatment while the procalcitonin level of one patient was 0.89 ng/mL. The dynamic observation showed that the procalcitonin level progressively increased and the procalcitonin level was 0.89 ng/mL when Plasmodium was found in the blood smear. Conclusions: The procalcitonin and CRP serum levels were significantly elevated among malaria patients. The majority of the patients recovered to the normal level within two weeks after effective antimalarial treatment and no longer suffered from recrudescence. However, the procalcitonin recovery level within two weeks after antimalarial treatment remained > 0.8 ng/mL. Hence, heightened alertness should be given to recrudescence.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.